🚀 VC round data is live in beta, check it out!
SyntekaBio Valuation Multiples
Discover revenue and EBITDA valuation multiples for SyntekaBio and similar public comparables like Intercure, Aligos Therapeutics, Dare Bioscience, J. Molner and more.
SyntekaBio Overview
About SyntekaBio
SyntekaBio Inc is a bioinformatics venture firm. It is engaged in gene-related research, technology development, and genetic analysis based on the genome big data platform and artificial intelligence deep learning drug development platform. The company manages and analyzes genome analysis and massive biodata and genome.
Founded
2009
HQ
Employees
41
Website
Financials (LTM)
EV
$36M
SyntekaBio Financials
SyntekaBio reported last 12-month revenue of $3M.
In the same LTM period, SyntekaBio generated had net loss of ($9M).
Revenue (LTM)
SyntekaBio P&L
In the most recent fiscal year, SyntekaBio reported revenue of $2M and EBITDA of ($8M).
SyntekaBio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3M | XXX | $2M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $2M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 100% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($8M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (365%) | XXX | XXX | XXX |
| EBIT Margin | (174%) | XXX | (307%) | XXX | XXX | XXX |
| Net Profit | ($9M) | XXX | ($12M) | XXX | XXX | XXX |
| Net Margin | (273%) | XXX | (497%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
SyntekaBio Stock Performance
SyntekaBio has current market cap of $42M, and enterprise value of $36M.
Market Cap Evolution
SyntekaBio's stock price is $2.30.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $36M | $42M | 0.0% | XXX | XXX | XXX | $-0.63 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSyntekaBio Valuation Multiples
SyntekaBio trades at 11.4x EV/Revenue multiple, and (4.2x) EV/EBITDA.
EV / Revenue (LTM)
SyntekaBio Financial Valuation Multiples
As of April 18, 2026, SyntekaBio has market cap of $42M and EV of $36M.
Equity research analysts estimate SyntekaBio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
SyntekaBio has a P/E ratio of (4.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $42M | XXX | $42M | XXX | XXX | XXX |
| EV (current) | $36M | XXX | $36M | XXX | XXX | XXX |
| EV/Revenue | 11.4x | XXX | 15.4x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (4.2x) | XXX | XXX | XXX |
| EV/EBIT | (6.6x) | XXX | (5.0x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 15.4x | XXX | XXX | XXX |
| P/E | (4.9x) | XXX | (3.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (4.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified SyntekaBio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
SyntekaBio Margins & Growth Rates
SyntekaBio's revenue in the last 12 month grew by 66%.
SyntekaBio's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.
SyntekaBio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 66% | XXX | 124% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (365%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 324% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 78% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 36% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 67% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 414% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
SyntekaBio Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| SyntekaBio | XXX | XXX | XXX | XXX | XXX | XXX |
| Intercure | XXX | XXX | XXX | XXX | XXX | XXX |
| Aligos Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Dare Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| J. Molner | XXX | XXX | XXX | XXX | XXX | XXX |
| Neurizon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SyntekaBio M&A Activity
SyntekaBio acquired XXX companies to date.
Last acquisition by SyntekaBio was on XXXXXXXX, XXXXX. SyntekaBio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by SyntekaBio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSyntekaBio Investment Activity
SyntekaBio invested in XXX companies to date.
SyntekaBio made its latest investment on XXXXXXXX, XXXXX. SyntekaBio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by SyntekaBio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout SyntekaBio
| When was SyntekaBio founded? | SyntekaBio was founded in 2009. |
| Where is SyntekaBio headquartered? | SyntekaBio is headquartered in South Korea. |
| How many employees does SyntekaBio have? | As of today, SyntekaBio has over 41 employees. |
| Is SyntekaBio publicly listed? | Yes, SyntekaBio is a public company listed on Korea Exchange. |
| What is the stock symbol of SyntekaBio? | SyntekaBio trades under 226330 ticker. |
| When did SyntekaBio go public? | SyntekaBio went public in 2019. |
| Who are competitors of SyntekaBio? | SyntekaBio main competitors are Intercure, Aligos Therapeutics, Dare Bioscience, J. Molner. |
| What is the current market cap of SyntekaBio? | SyntekaBio's current market cap is $42M. |
| What is the current revenue of SyntekaBio? | SyntekaBio's last 12 months revenue is $3M. |
| What is the current revenue growth of SyntekaBio? | SyntekaBio revenue growth (NTM/LTM) is 66%. |
| What is the current EV/Revenue multiple of SyntekaBio? | Current revenue multiple of SyntekaBio is 11.4x. |
| Is SyntekaBio profitable? | No, SyntekaBio is not profitable. |
| What is the current net income of SyntekaBio? | SyntekaBio's last 12 months net income is ($9M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.